Pirfenidone for idiopathic pulmonary fibrosis, thrombocytosis in chronic obstructive pulmonary disease exacerbations, and a longitudinal study on e-cigarettes

Affiliations

Comment

Sugeet Jagpal et al. Am J Respir Crit Care Med. 2014.

. 2014 Sep 15;190(6):699-700.

doi: 10.1164/rccm.201406-1188RR.

¹ Pulmonary and Critical Care Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey.

No abstract available

Comment on

A longitudinal analysis of electronic cigarette use and smoking cessation.
Grana RA, Popova L, Ling PM. Grana RA, et al. JAMA Intern Med. 2014 May;174(5):812-3. doi: 10.1001/jamainternmed.2014.187. JAMA Intern Med. 2014. PMID: 24664434 Free PMC article. No abstract available.
Thrombocytosis is associated with increased short and long term mortality after exacerbation of chronic obstructive pulmonary disease: a role for antiplatelet therapy?
Harrison MT, Short P, Williamson PA, Singanayagam A, Chalmers JD, Schembri S. Harrison MT, et al. Thorax. 2014 Jul;69(7):609-15. doi: 10.1136/thoraxjnl-2013-203996. Epub 2014 Apr 17. Thorax. 2014. PMID: 24743560
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, Lederer DJ, Nathan SD, Pereira CA, Sahn SA, Sussman R, Swigris JJ, Noble PW; ASCEND Study Group. King TE Jr, et al. N Engl J Med. 2014 May 29;370(22):2083-92. doi: 10.1056/NEJMoa1402582. Epub 2014 May 18. N Engl J Med. 2014. PMID: 24836312 Clinical Trial.